MarketBeat
11 Jul 2026, 02:02 UTC · 16w ago
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
Impact · against what's priced in
RxSight faces a significant near-term valuation headwind as organic sales plummeted 20% due to competitive pressure and weak consumer sentiment. While the Alcon collaboration and margin expansion provide a long-term floor and 2026 optimism, they do not offset the immediate deterioration of the core business growth profile.
- RXST−0.40
No priced-in read yet
- In context
Preliminary Q2 organic sales fell 20% year-over-year, driven by competitive trialing and softer consumer sentiment, though this is partially mitigated by a new Alcon partnership and a raised gross margin outlook to 73%-75%.
Read from the article alone
